I am going to focus on the clinical aspects of fat redistribution and bone abnormalities in HIV-infected patients.
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Toward an objective definition of lipodystrophy There has been some progress towards a definition of fat redistribution associated with HIV or antiretroviral therapy. We discuss lipodystrophy in spite of the lack of a standard definition. Patients with lipodystrophy characteristically have fat accumulation in the abdomen, peripheral fat loss in the extremities, and significant fat loss in the face. We recognize lipodystrophy in patients, but need an objective definition that can be used across sites and in studies.
A study by Andrew Carr of the University of New South Wales in Sydney, Australia tried to create an objective definition of lipodystrophy by following the rheumatology model. Rheumatologic diseases are also difficult to define. Clinicians can identify typical lupus, but two patients with lupus can be quite different, creating a lot of gray areas for a precise definition. Criteria were developed for the diagnosis of rheumatologic diseases when clinicians agreed that patients had rheumatologic diseases, found common characteristics, and made those characteristics part of the definition.
Carr and David Cooper, also from the University of New South Wales, organized a large trial in 32 sites all over the world with 1,081 patients. There were 471 cases of people with lipodystrophy as defined by the primary doctors and the patients. To be diagnosed with lipodystrophy, both the primary doctor and the patient needed to agree that the patient had problems with fat redistribution. This was the "gold standard" used in the study. Investigators did not distinguish between fat loss and fat accumulation, although people with only fat accumulation in the abdomen were not included in the study. There were 371 controls who did not meet the definition of lipodystrophy from the same clinics, and 288 people who were not assigned a diagnosis in the absence of an agreement between the physician and patient. Investigators developed mathematical models to determine a definition of lipodystrophy. They evaluated the sensitivity and specificity of that definition, compared to the "gold standard" or agreement between the patient and the doctor. They selected criteria that included female gender; age over 40; HIV-positive for more than four years; increased waist to hip ratio; decreased high-density lipoprotein (HDL) cholesterol; increased anion gap; decreased leg fat in a bone densitometry (DEXA) scan; increased visceral adipose tissue area (VAT) to subcutaneous adipose tissue area (SAT) ratio; and increased trunk to limb fat ratio. The presence or absence of variables led to a score that predicted lipodystrophy with a sensitivity of 79 percent and specificity of 90 percent (Figure 1) . The sensitivity and specificity was not great, leading to questions about the clinical utility of this definition. This definition is a little circular and probably has limited utility for the clinician. A physician thinks the patient has the syndrome (the "gold standard") and does the tests to prove the patient has the syndrome. It also clearly points out the limits of cross-sectional studies. We do not know the starting point of these patients. It is very difficult to know how much fat loss is due to antiretrovirals or due to the patient's own phenotype. In summary, the study is an effort in the right direction, but not the final answer. Getting around this problem requires longitudinal studies that include an objective and subjective evaluation. While doing DEXA scans and computed tomography (CT) scans, investigators need to ask patients whether they are losing fat, and to ask physicians whether there is a problem with patient fat redistribution. By doing this, we will find thresholds of body fat changes that are clinically significant for both the patient and the provider, and we will be able to come out with an objective definition. This is the only way to know how fast people lose fat when they start antiretroviral therapy, and to be able to define these syndromes prospectively.
Some ongoing studies will be also very important in defining lipodystrophy, particularly the Fat Redistribution and Metabolic Change in HIV Infection (FRAM) study. FRAM is a large, well-controlled, cross-sectional study by Carl Grunfeld of the University of Southern California at San Francisco. FRAM has the benefit of a large non-HIV cohort, allowing comparisons between HIV-infected and non-infected individuals, and evaluations to determine which of these changes are HIV-specific and what changes are age-and gender-related, independent of HIV or its treatment. A limiting problem with FRAM is its cross-sectional nature.
Another important longitudinal study is AIDS Clinical Trials Group (ACTG) 5005s, which is a substudy of ACTG 384. ACTG 384 evaluated zidovudine (ZDV)/lamivudine (3TC) or stavudine (d4T)/didanosine (ddI) with efavirenz (EFV), nelfinavir (NFV), or both. It used DEXA scans collected in follow-ups of a large subgroup of about 130 patients. The data will be very important because of the longitudinal nature of the study. It will tell us how fast patients lose fat, frequency of the problem, and what we should expect after starting antiretroviral therapy. We need this kind of longitudinal data to make a clear definition and description of these syndromes.
Editor's Note: Metabolic data from ACTG 5005/384 were concluded in May 2003. The data identify several predictors for glucose or lipid dysfunction and body fat distribution abnormalities. Following is an abbreviated abstract entitled, "Prospective study of regional body composition in antiretroviral-naive subjects randomized to receive zidovudine + lamivudine (ZDV + 3TC) or didanosine + stavudine (ddI + d4T) combined with nelfinavir (NFV), efavirenz (EFV), or both: ACTG 5005s, a substudy of ACTG 384," which was presented by Dubé MP et al at the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (September 22-25, 2002, in San Diego, California) :
Background: The role of different antiretroviral agents in causing body fat changes remains controversial. Cross-sectional and observational studies have been limited by the effects of prior therapies, and the lack of randomization or longitudinal assessments. Conclusions: Antiretroviral-naive subjects randomized to ddI + d4T lost a greater proportion of limb fat than those receiving ZDV + 3TC at weeks 48 to 80. Subjects randomized to NFV lost a greater proportion of limb fat at week 80 than with EFV. Although trunk fat increased across all groups, regimen-specific differences in trunk fat changes were not detected. Analysis of metabolic variables and self-perceived body image is needed to evaluate the clinical significance of these findings.
Potential pathogenic mechanisms and risk factors for lipodystrophy
Several potential pathogenic mechanisms or risk factors are thought to be responsible or associated with lipodystrophy. Some people think fat lipoatrophy might be related to mitochondrial toxicity and have presented supportive data. One study showed that patients with significant fat lipoatrophy have decreased mitochondrial DNA content in the adipose tissue. Age seems to be a risk factor for the development of lipoatrophy; the older you are, the more likely you are going to have this syndrome. There is also a genetic predisposition. Not everybody on HIV treatment gets this problem. Immune recovery associated with treatment might play a role in the development of fat lipoatrophy. As for hormonal factors, it seems fat accumulation is more frequent in females, and fat lipoatrophy is more frequent in males. And last, HIV probably plays a role in these problems.
All these risk factors are interrelated with one another, and the relative contribution of each one is unknown. Regarding therapy-related factors, nucleoside drug history might be associated with lipoatrophy. Lately, the main culprit seems to be d4T. But the association with d4T has only been seen in cross-sectional studies, and it is impossible in cross-sectional studies to assess causality.
Other host factors such as age, and HIV factors such as duration of illness, rate of illness, and low CD4 count seem to play a role in the development of these problems ( Figure 2 ).
There are obvious biases in these studies, particularly "wish bias" by the investigators. "Wish bias" is the tendency for investigators to make causal conclusions primarily on the basis of their own published results.
There is an inherent tendency in all of us to desire a specific finding. For example, an investigator who studies toxicities of drugs sometimes attributes observations to drug toxicities when the drugs might not have anything to do with what is seen.
Host-related factors
Regarding patient-related factors for the development of lipodystrophy, some interesting preliminary data from the HIV Outpatient Study (HOPS) cohort have been presented. Although the study did not use objective measures of fat redistribution, it was a longitudinal survey. We do not have data from baseline, but we have data in two consecutive years. The incidence of lipoatrophy depended on the nadir CD4 count. There seems to be a direct relationship between these two variables; if you start with a lower CD4 count and do not increase your CD4 cell count, the probability of having lipoatrophy is greater than if you responded to therapy.
The higher incidence of lipoatrophy may have some relationship to the lack of immune reconstitution, or with the immune activation that is associated with ongoing HIV replication ( Figure 3 ).
Massimo Galli of the University of Milan in Italy has also presented data from a European cohort with 600 females out of more than 2,000 patients. Female gender was an independent risk factor for lipodystrophy, mainly for fat accumulation with an odds ratio of two. Clearly, there are gender differences in the incidence of these syndromes that make lipoatrophy more common in males than in females, and fat accumulation and mixed phenotypes more common in women.
Treatment-related factors
Nucleosides and protease inhibitors (PIs) seem to have an additive effect on the incidence of lipoatrophy. Simon Mallal of the Royal Perth Hospital in Western Australia evaluated the probability of remaining free of lipoatrophy based on the patient's antiretroviral regimen. If the patients were on dual therapy with only nucleosides, they were less likely to develop lipoatrophy than if they were on triple therapy that included a PI. If they were on triple therapy, the probability of developing lipoatrophy went up, suggesting an additive effect of nucleosides and PIs (Figure 4 ). Regarding the role of nucleoside reverse transcriptase inhibitors (NRTIs), there are data suggesting that d4T might be more toxic for the development of fat lipoatrophy, and that more patients are going to develop lipoatrophy on a d4T-containing regimen ( Figure 5 ).
Regarding the specific role of d4T in the development of lipoatrophy, some interesting data was recently presented from a study by (D. William) Cameron of the University of Ottawa at The Ottawa Hospital in Canada, and (Calvin) Cohen of the Community Research Initiative of New England in Boston. In this study, some patients were treated with nucleosides, and others did not receive nucleosides. Patients were receiving ritonavir (RTV) plus saquinavir (SQV) alone, and some of those patients needed treatment intensification with nucleoside analogs. At a five-year follow-up, most of the patients who were intensified (37/65 remained in the trial) took d4T and 3TC, which at that time was the most popular nucleoside combination. Patients on RTV/SQV alone without nucleosides showed no difference in the incidence of fat accumulation when compared to patients who received nucleosides, suggesting that fat accumulation might be more related to the PI component of the regimen. However, when the investigators looked at fat depletion, there was a clear difference between the two groups. The patients who intensified therapy with nucleosides after 12 weeks were more likely to develop lipoatrophy. There was an odds ratio around four, and a wide confidence interval because the sample size was not very big. The data suggest that nucleosides might be more related to lipoatrophy than PIs, something that almost everybody recognizes nowadays. However, the study has serious limitations: it was a survey without an objective measurement of fat. This could create a systematic recall bias because of the perceptions about the use of d4T.
Treatment options for fat redistribution
There have been many studies about treatment options presented over the last year for fat redistribution. Specifically, for fat accumulation, (Steven) Grinspoon of Harvard Medical School in Boston looked at metformin. Metformin was evaluated in patients who had insulin resistance and fat accumulation. These patients were randomized to receive metformin 500 mg twice daily, a relatively low dose because of concerns for lactic acidosis. There was also a control group not on metformin. Patients who took metformin had a decrease in the amount of intra-abdominal fat, and improvement in all of the measures of insulin resistance. This effect of metformin on insulin resistance may be mediated through loss of abdominal fat. However, patients who received metformin tended to lose subcutaneous fat as well, making metformin an unlikely treatment option for patients with significant lipoatrophy.
For fat lipoatrophy, there is a still hope for the use of rosiglitazone and glitazones. Troglitazone has recently been taken off the market, but a group from Finland studied rosiglitazone, a different drug from the same group. This study evaluated the use of rosiglitazone and its effects on morphologic changes, mainly fat accumulation but also lipoatrophy. Thirty patients used a relatively high dose of rosiglitazone once a day. It was a short 24-week study that used magnetic resonance imaging (MRI) to assess changes in fat. They observed a decreased insulin resistance, and surprisingly a significant increase in triglycerides in patients on rosiglitazone, but no changes in fat stores. When the authors looked at subcutaneous fat and changes in fat tissue at 24 weeks, there was no difference in the rosiglitazone arm when compared to the placebo arm. There also was no change in fat accumulation. The study was obviously underpowered to detect difference in 24 weeks, but it was a negative study that led the ACTG to close a planned study that was going to evaluate rosiglitazone for this indication.
A currently ongoing Australian study uses rosiglitazone (ROSEY) over 48 weeks, rather than 24 weeks for the treatment of lipoatrophy. The ROSEY study has 50 patients per arm and has more power to detect a difference in percent increase in limb fat. I am glad the Australians are taking the risk to move ahead with ROSEY. I also understand why the ACTG decided not to go ahead with their trial.
Study to watch
A study to watch is ACTG 5082 that looks at fat accumulation and insulin resistance in a control arm and three treatment arms: metformin, rosiglitazone, and a combination of both. It will tell us a lot about fat accumulation as well as lipoatrophy.
Switch studies
Three studies looking at drug switches and their effect in fat redistribution have recently been presented. The rationale to do these studies comes from observational studies that retrospectively looked at patients who had stopped d4T, and had improvement in fat lipoatrophy. The first one, known as the "Mitox" study, was presented by Carr. In this study, patients on d4T or ZDV were randomized to be "switched" or not, to abacavir (ABC). Patients who switched ZDV or d4T to ABC gained 0.3 kg of fat at 24 weeks, measured by DEXA scans, but neither patients nor doctors felt that there was a clear improvement. There was another similar study by Grace McComsey of Case Western Reserve University in Cleveland, Ohio.
The study switched d4T to ZDV or ABC, and showed consistent results: improvements in peripheral fat in the individuals who switched therapy. Another Australian study confirmed the same results. In conclusion, switching off d4T improves the fat in your extremities at six months by approximately 0.3 kg, which is not a big fat gain when divided by four extremities in a 60 kg adult.
The main limitations of these three studies are whether the increases are really clinically significant, and the short follow-up. We do not know the kinetics of fat loss, so we do not know how long it is going to take for our populations to start seeing improvements.
What are the effects of stopping nucleosides and using a PI/non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen? ACTG 5110 will ask this question in a study with two arms. All patients will switch antiretrovirals; some immediately, and some after a delayed switch. One arm switches d4T or ZDV to ABC, while the other arm switches off nucleosides and goes to an NNRTI plus PI-based regimen.
Surgery for the treatment of lipoatrophy
Several studies evaluated the use of surgery for lipoatrophy. One study showed remarkable aesthetic results for patients with facial lipoatrophy who had injections of polylactic acid in the cheeks. Other compounds have also been used in injections such as New-Fill and glucogen. This treatment of lipoatrophy is more common in Europe than in the United States because insurance companies cover the expenses of these surgical procedures.
Osteopenia/osteoporosis I would like to discuss osteopenia/osteoporosis during the second part of my presentation. Mary Romeyn of the University of California at San Francisco, and Julia Ireland of the University of Southern California in Los Angeles introduced us to this problem in 1999 in France. They presented 20 patients with low CD4 count and a very high frequency of osteopenia/osteoporosis.
Definitions of osteopenia/osteoporosis
In contrast with fat lipodystrophy, there is no problem with the definition of osteoporosis. The definition of osteopenia/osteoporosis is based on DEXA t-scores. T-scores are normalized bone density scores, comparing the patient's bone mineral density to the bone mineral density of a person of the same gender and race at age 30. You have osteopenia if your t-score is between -1 to -2.5, and you have osteoporosis if it is less than -2.5 ( Figure 6 ).
Is osteopenia/osteoporosis related to HIV or antiretroviral therapy? It is a classic "the chicken or the egg" question, just as for many of the metabolic complications. The role of HIV itself has not been separated clearly from drug effects and other factors. Figure 7 shows the graph in our original paper where patients were classified in three groups: patients receiving PI-based treatment, PI-naive patients, and HIV-negative controls. The group receiving PIs had lower bone mineral density, although, as in all crosssectional studies, we could not blame a specific class of drugs as being responsible for this problem. Other studies have shown that osteopenia/osteoporosis is more frequent in HIV-infected patients than in HIVnegative patients, but there is no clear difference between patients on PIs and patients not on PIs.
Association of HIV itself and osteopenia/osteoporosis
Gilead presented data on the association of osteopenia/ osteoporosis with HIV itself in a study that compared d4T, 3TC, and EFV versus tenofovir (TFV), 3TC, and EFV. Investigators had a large amount of bone data because TFV was associated with bone loss in dogs, so they wanted to look at the effects of this drug in humans. The patients were never on antiretroviral drugs. The prevalence of osteopenia/osteoporosis was around 26 percent versus the expected 16 percent. Our cohort saw around 46 percent prevalence, possibly because the patients were sicker for a longer period of time.
Association of osteopenia/osteoporosis with HIV treatment
Our cross-sectional data showed the probability of having osteopenia/osteoporosis in patients treated with antiretroviral treatment was approximately 50 percent, versus 20 percent in HIV-positive patients on no PIs, and non-HIVpositive patients. So patients on PI-based regimens were more likely to have osteopenia/osteoporosis. Our conclusion was that patients on long-term treatment might suffer an accelerated loss of bone mineral density.
Based on that cross-sectional study, we looked longitudinally and prospectively at a different cohort of patients in our clinic. In this prospective study of 125 patients, we collected more information about HIVrelated factors and classic risk factors for osteopenia/ osteoporosis. The only HIV-related factor significantly associated with osteopenia/osteoporosis was the duration of HIV. The longer you had HIV, the more likely you were going to have osteopenia, suggesting that HIV itself might be a contributor to this problem. There were no differences in the mean nadir CD4, in the current CD4, in the current viral load, and in incidence of this problem between females and males, or race. Among "classic"-related factors, the current weight in patients with osteopenia/osteoporosis was lower than in people who did not have osteopenia. The body mass index (BMI) was also lower. Patients with osteopenia/osteoporosis had a higher probability of having a history of significant weight loss. The same was true if the current weight was less than 90 percent of the ideal body weight, or if the patient had a history of a BMI less than 20, which is a criterion for "wasting" syndrome. Previous use of steroids was more associated with osteopenia and osteoporosis, and history of smoking was also more frequent in patients with osteopenia than in patients that did not have osteopenia.
We looked at treatment-related factors in two ways. We counted the mean number of days on an NRTI-based regimen, NNRTI-based regimen, or PI-based regimen, and evaluated if the total drug exposure was associated with this problem. We evaluated if there was a threshold. Total drug exposure was not associated with osteopenia/osteoporosis. The only treatment trend associated with osteopenia was having taken a PI at some time in the past, but the association was not statistically significant (p = 0.09).
We also looked longitudinally at these patients (Figure 8 ). To our surprise, they did not keep losing bone, but gained a statistically significant 3 percent amount of bone after 72 weeks of follow-up. Looking over time at patients who were on and not on PI-based regimes, there was no difference between these two groups. We excluded people who started on alendronate. The bone markers did not change over time either. Curiously, these patients tended to have high alkaline phosphatase, and high osteocalcium levels, suggesting a state of high bone remodeling. The urinary bone markers also tended to be high.
This second study confirmed the high 46 percent prevalence of osteopenia/osteoporosis among HIVinfected patients. "Classic" risk factors for low bone mineral density were statistically significant predictors of osteopenia. There was a trend towards a lower bone mineral density in patients who had been on a PI at some time, although this association disappeared after controlling for other known risk factors for osteopenia with multivariate analysis. During the longitudinal follow-up, there was a significant increase in bone mineral density, regardless of the type of antiretroviral therapy (Figure 9 ).
These clinical data suggest that osteopenia is a frequent problem among HIV-infected individuals. Treatment might contribute to osteopenia, but the problem seems to be more related to HIV itself.
Treatment of osteopenia/osteoporosis
The general recommendation is to tell patients to take calcium and Vitamin D, and to exercise. There are no studies that address specifically the treatment of osteopenia/ osteoporosis. We are conducting a small, randomized trial in 30 patients to detect small changes in bone mineral density. There is reason to think that alendronate will not work in this population. ACTG is doing a larger trial (ACTG 5163) with 50 or possibly 60 patients to see whether alendronate may treat osteopenia/osteoporosis. ■ Figure 9 
